17:00 Thu 25 Jun 2020
ReNeuron Group plc - New Exosome Research Collaboration
| AIM: RENE |
ReNeuron Group plc
("
This latest research collaboration will focus on the use of
The research evaluation agreement is in line with
Commenting on the agreement,
ENDS
Contacts:
ReNeuron |
+44 (0) 20 3819 8400 |
Olav Hellebø, Chief Executive Officer | |
Michael Hunt, Chief Financial Officer | |
Buchanan (UK Media/Investor Relations) |
+44 (0) 20 7466 5000 |
Mark Court, Tilly Abraham | |
Claudia Styslinger, David Rosen |
+1 212 600 1902 |
|
|
Jonathan Senior, Stewart Wallace, Ben Maddison | +44 (0) 20 7710 7600
|
N+1 Singer (Joint Broker) Aubrey Powell, James Moat, Tom Salvesen |
+44 (0) 20 7496 3000 |
|
|
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa, and for disability as a result of stroke.
ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain. The Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com.
This information is provided by RNS, the news service of the
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
FOR OUR FULL DISCLAIMER CLICK HERE